Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis

Kong, Xiangyu; Du, Yiqi; Wang, Guokun; Gao, Jun; Gong, Yanfang; Li, Lei; Zhang, Zhuo; Zhu, Jiaqi; Jing, Qing; Qin, Yongwen; Li, Zhaoshen
February 2011
Digestive Diseases & Sciences;Feb2011, Vol. 56 Issue 2, p602
Academic Journal
journal article
Background: MicroRNAs (miRNAs) have long been established to remain stable in circulation, and dysregulated miRNAs in serum of tumor patients could potentially serve as novel biomarkers.Aims: To determine whether certain serum miRNAs could represent potential diagnostic and prognostic biomarkers for pancreatic ductal adenocarcinoma (PDAC).Methods: About 35 patients diagnosed with PDAC at different stages between August 2007 and January 2009 were enrolled in this study. Sera from 15 chronic pancreatitis (CP) patients and 15 healthy individuals were treated as controls. Quantitative real-time polymerase chain reaction assays specific to mature miRNAs were used to quantify the relative levels of those PDAC-associated serum miRNAs.Results: Of the seven miRNAs detected, three were identified as differentially expressed in PDAC and control groups. miR-21 was able to distinguish PDAC patients from CP (p = 0.033) and healthy subjects (p = 0.001), whereas miR-155 and miR-196a were able to differentiate sera with sick pancreas (PDAC/CP) from normal pancreas (p = 0.0002 and 0.010, respectively). Serum miR-196a expression levels in unresectable PDAC (stages III and IV) patients were significantly higher than those in resectable (stages I and II) patients (p = 0.001). Furthermore, serum miR-196a expression level was found to have a potential value in predicting median survival time of PDAC patients (high-level miR-196a, 6.1 months, (95% CI, 4.49-7.72) versus low-level miR-196a, 12.00 months, (95% CI, 5.92-18.08), p = 0.007).Conclusions: Serum miR-196a could be a potential noninvasive marker for PDAC prognosis and selection of laparotomy.


Related Articles

  • Utilization of CDX2 Expression in Diagnosing Pancreatic Ductal Adenocarcinoma and Predicting Prognosis. Xiao, Wenbin; Hong, Hong; Awadallah, Amad; Zhou, Lan; Xin, Wei // PLoS ONE;Jan2014, Vol. 9 Issue 1, p1 

    CDX2, a master transcriptional regulator of intestinal cell differentiation and survival, has been used as a marker to indicate colorectal lineage in adenocarcinomas of unknown origin. Pancreatic ductal adenocarcinoma (PDAC) is one of the most common causes for adenocarcinomas of unknown origin,...

  • Pancreaticoduodenectomy for pancreatic cancer: The Verona experience. MALLEO, GIUSEPPE; MARCHEGIANI, GIOVANNI; SALVIA, ROBERTO; BUTTURINI, GIOVANNI; PEDERZOLI, PAOLO; BASSI, CLAUDIO // Surgery Today;Apr2011, Vol. 41 Issue 4, p463 

    Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer-related mortality in the Western world. The current treatment is multimodal, and in resectable patients radical surgery represents the key-step toward long-term survival. Pancreaticoduodenectomy (PD) is the most widely...

  • Comparative proteomic analysis for the detection of biomarkers in pancreatic ductal adenocarcinomas. Qi, T.; Han, J.; Cui, Y.; Zong, M.; Liu, X.; Zhu, B. // Journal of Clinical Pathology;Jan2008, Vol. 61 Issue 1, p49 

    Aims: To search for novel potential protein biomarkers for the early detection and better intervention of pancreatic ductal adenocarcinoma (PDAC). Methods: Eight pairs of matched PDAC and non-cancerous pancreas tissues were profiled with two-dimensional electrophoresis; differentially expressed...

  • Multiple functions of hypoxia-regulated miR-210 in cancer. Qin Qin; Wei Furong; Li Baosheng // Journal of Experimental & Clinical Cancer Research (17569966);2014, Vol. 33 Issue 1, p1 

    MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression posttranscriptionally. miRNAs can be induced by a variety of stresses such as hypoxia, and are involved in diverse biological processes including differentiation, cell proliferation, cell death, and tumorigenesis. Hypoxia,...

  • BAG3 Is a Novel Serum Biomarker for Pancreatic Adenocarcinomas. Falco, Antonia; Rosati, Alessandra; Festa, Michelina; Basile, Anna; De Marco, Margot; d'Avenia, Morena; Pascale, Maria; Dal Piaz, Fabrizio; Tavano, Francesca; Di Mola, Fabio Francesco; di Sebastiano, Pierluigi; Berloco, Pasquale Bartolomeo; Nudo, Francesco; Caraglia, Michele; Febbraro, Antonio; Barcaroli, Daniela; Scarpa, Aldo; Pezzilli, Raffaele; De Laurenzi, Vincenzo; Turco, Maria Caterina // American Journal of Gastroenterology;Jul2013, Vol. 108 Issue 7, p1178 

    The article focuses on pancreatic ductal adenocarcinoma (PDAC), which is one of the five most lethal malignancies and states that it was found that the intracellular anti-apoptotic protein BAG3 used to get expressed in PDAC tumor patients, according to a report. It further investigated whether...

  • Intraductal papillary mucinous carcinoma of the pancreas associated with pancreas divisum: a case report and review of the literature. Takeshi Nishi; Yasunari Kawabata; Noriyoshi Ishikawa; Asuka Araki; Seiji Yano; Riruke Maruyama; Yoshitsugu Tajima // BMC Gastroenterology;Jul2015, Vol. 15 Issue 1, p1 

    Background: Pancreas divisum, the most common congenital anomaly of the pancreas, is caused by failure of the fusion of the ventral and dorsal pancreatic duct systems during embryological development. Although various pancreatic tumors can occur in patients with pancreas divisum, intraductal...

  • Clinical Characteristics and Overall Survival in Patients with Anaplastic Pancreatic Cancer. CLARK, CLANCY J.; ARUN, JANANI S.; GRAHAM, RONDELL P.; LIZHI ZHANG; FARNELL, MICHAEL; REID-LOMBARDO, KAYE M. // American Surgeon;Feb2014, Vol. 80 Issue 2, p117 

    Anaplastic pancreatic cancer (APC) is a rare undifferentiated variant of pancreatic ductal adenocarcinoma with poor overall survival (OS). The aim of this study was to evaluate the clinical outcomes of APC compared with differentiated pancreatic ductal adenocarcinoma. We conducted a...

  • Improved Pancreatic Adenocarcinoma Diagnosis in Jaundiced and Non-Jaundiced Pancreatic Adenocarcinoma Patients through the Combination of Routine Clinical Markers Associated to Pancreatic Adenocarcinoma Pathophysiology. Ferri, María José; Saez, Marc; Figueras, Joan; Fort, Esther; Sabat, Miriam; López-Ben, Santiago; de Llorens, Rafael; Aleixandre, Rosa Núria; Peracaula, Rosa // PLoS ONE;1/25/2016, Vol. 11 Issue 1, p1 

    Background: There is still no reliable biomarker for the diagnosis of pancreatic adenocarcinoma. Carbohydrate antigen 19–9 (CA 19–9) is a tumor marker only recommended for pancreatic adenocarcinoma follow-up. One of the clinical problems lies in distinguishing between this cancer...

  • Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma. Ormanns, Steffen; Altendorf-Hofmann, Annelore; Jackstadt, Rene; Horst, David; Assmann, Gerald; Zhao, Yue; Bruns, Christiane; Kirchner, Thomas; Knösel, Thomas; Knösel, Thomas // British Journal of Cancer;11/17/2015, Vol. 113 Issue 10, p1460 

    Background: Frequent disease relapse and a lack of effective therapies result in a very poor outcome in pancreatic ductal adenocarcinoma (PDAC) patients. Thus, identification of prognostic biomarkers and possible therapeutic targets is essential. Besides their function in cell-cell...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics